Seeking Alpha

Olysio cleared in Europe

  • The European Commission approves J&J (JNJ) unit Janssen Pharmaceuticals' Olysio (simeprivir) for the treatment of Hepatitis C genotype 1 and 4 infection in combination with other medicines.
  • Olysio is already approved for sale in the U.S., Japan, Canada and Russia. It will be available in the EU in 2H 2014.
  • Related tickers: (GILD) (ABBV) (BMY) (MRK)
Comments (3)
  • wam350
    , contributor
    Comments (112) | Send Message
    More good news.
    16 May, 09:50 AM Reply Like
  • Salty32
    , contributor
    Comment (1) | Send Message
    What impact does this have on the demand for Gilead's Hep C drug?
    16 May, 12:39 PM Reply Like
  • User 25598103
    , contributor
    Comment (1) | Send Message
    Fine, if the price is acceptable.
    16 May, 02:42 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: